Relevant Articles About Research and Clinical Trials in Breast Cancer
Trusted insights straight to your inbox and get the latest updates from OncWeekly
KEY TAKEAWAYS The study aimed to assess serum fibronectin and gene polymorphisms as predictors of recurrence and treatment response in patients with NMIBC on BCG therapy. Researchers found elevated serum fibronectin predicts early recurrence in NMIBC but not BCG...
KEY TAKEAWAYS The study aimed to estimate the global prevalence of GIM through a systematic review and meta-analysis. The results showed the global prevalence of GIM is high, requiring further investigation and attention. Sara Soroorikia and the team aimed to...
KEY TAKEAWAYS The study aimed to investigate the role of CD247 and CD4 expression in TNBC prognosis. The results showed low CD247 and CD4 expression predicts poor outcomes in patients with TNBC. Ankit Pateriya and the team aimed to evaluate the prognostic...
The A-Brave phase 3 trial aimed to investigate the efficacy of avelumab as an adjuvant treatment for high-risk early TNBC. The Co-primary endpoint …
The PATRICIA II phase 2 trial aimed to compare palbociclib + T + ET with TPC in HER2+ HR+ PAM50 Luminal ABC. The …
The Young-PEARL phase 2 trial aimed to compare long-term survival outcomes with exemestane + palbociclib with OFS vs. capecitabine in patients with mBC. …
Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, …
Background Adoptive cell transfer (ACT) shows promise as an immunotherapy for melanoma and other cancers. However, there are several challenges associated with ACT such as the logistical complexity and inconsistency when using patient-derived antigen-presenting cells for …
Background Immune checkpoint inhibitors (ICIs) are standard therapy for advanced hepatocellular carcinoma (HCC). However, the efficacy of combining nivolumab and ipilimumab in Anti-PD(L)-1 Naïve and Experienced HCC patients remains unclear. Methods We retrospectively reviewed 23 patients with advanced …
Background Novel early-line therapies for advanced (unresectable or metastatic) melanoma are needed to improve the rate of deep and durable responses and increase the proportion of patients with long-term benefit. TILVANCE-301 will evaluate the efficacy and …